Innate Pharma Sa Class A · EURONEXT:IPH
Innate Pharma Sa Class A — Investor Presentation (May 2024)
42 slides from Innate Pharma Sa Class A's investor presentation, May 2024
Slide 1: Company overview
’ ®irdhate (phage " | a Company Als overview \4 ¥- \Y 2024 EURONEXT : IPH.PA NASDAQ: IPHA h
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. 2
Slide 3: Key Takeaways
Key Takeaways Create value for patients and shareholders Established expertise in immuno-pharmacology • LACUTAMAB TELLOMAK DATA • Top-line results in mycosis fungoides to be shared at ASCO • Regulatory strategy • EXPAND ANKET® CLINICAL PORTFOLIO – LEAD IN HEMATOLOGY INDICATIONS • First patient dosed
Slide 4: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) Delivering across our strategic objectives • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201 (CD39) MATISSE | Phase 2 readout (AZ) • IPH5301 (CD73) | Phase 1 data • SAR’579 / IPH6101 ANKET® (CD123) | Next steps (S
Slide 5: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Comments Lacutamab KIR3DL2 Sezary syndrome / MF Phase 2 TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) MF data ASCO 2024 Monoclonal antibodies PTCL Phase 2 KILT IST with LYSA IPH5301
Slide 6: Innate Pharma snapshot
Innate Pharma snapshot Global, clinical-stage oncology-focused biotech company. Scientific excellence in the field of innate immunity with expertise in Natural Killer (NK) cell biology and antibody engineering. Focused pipeline of antibodies, including several potentially first-in-class clinical and
Slide 7: Scientific innovation drives our strategy
Scientific innovation drives our strategy Our ambition – ANKET® & ADC leverage our scientific know-how in innate Build a sustainable Lacutamab Advance our immunity and antibody engineering to business through Drive near-term value innovative develop cancer drugs that improve the Drive near-term val
Slide 8: Innate's approach: harnessing innate immunity in cancer
Priming and activation (APCs and T cells) Innate’s approach: harnessing innate immunity in cancer Cancer antigen presentation (DCs) Choosing the right targets to leverage the body’s immune response Lymph node Trafficking of 01 Amplification of the innate immune response T cells to tumors Engage NK c
Slide 9: Building a robust pipeline on strong basics
Building a robust pipeline on strong basics Validated Strong track Robust Science record of pipeline collaborations 7 drug candidates in clinical stage Including 3 proprietary and 4 in partnerships 9
Slide 10: Lacutamab: Drive near-term value
Lacutamab Drive near-term value 10
Slide 11: Lacutamab: lead proprietary asset
LACUTAMAB Lacutamab: lead proprietary asset First-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL) and Peripheral T Cell Lymphomas (PTCL). Compelling Phase 1 data in Sezary syndrome (SS), published
Slide 12: Compelling Phase 1 Results Sezary Syndrome Subgroup
LACUTAMAB Compelling Phase 1 Results Sezary Syndrome Subgroup (n=35) FDA Fast Track Designation granted based on these results. Total 44 patients with CTCL ≥ 2 lines of therapy • 25 (incl. 20 SS) in dose escalation (intra-patient dose escalation was allowed). • 19 (incl. 15 SS) in cohort expansion.
Slide 13: Lacutamab | Development strategy
LACUTAMAB Lacutamab | Development strategy A potential new standard of care in T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lymphoma Sézary syndrome ~ 80 - 200 patients1 Fast to market ~90% KIR3DL2 expression* approach Niche indication with high unmet need Mycosis fungoides (MF) ~ 2,200 – 4,
Slide 14: Lacutamab | Development strategy
LACUTAMAB Lacutamab | Development strategy A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lymphoma TELLOMAK Sézary syndrome Phase 2 Trial Sézary syndrome 80-200 patients Phase 2 ~90% KIR3DL2 expression Cohort 1 (N~60) 3 cohorts (N~100) ASH 2023 Minimum o
Slide 15: Lacutamab | Sézary syndrome Phase 2 data
LACUTAMAB Lacutamab | Sézary syndrome Phase 2 data Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial Patient characteristics Data cutoff: May 1, 2023 56 post mogamulizumab patients with advanced, highly refractory and heavily pre-treated dise
Slide 16: Lacutamab | Sézary syndrome patient cases
LACUTAMAB Lacutamab | Sézary syndrome Phase 2 data Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Patients cases Patient Case #1, ongoing Patient Case #2, ongoing • 58-year-old female • 51-year-old female • 10 previous lines of therapy • 6 previous systemic lines of therapy • St
Slide 17: Lacutamab | Preliminary Mycosis fungoides efficacy results
LACUTAMAB Lacutamab | Preliminary Mycosis fungoides efficacy results Mycosis fungoides Cohort 2 - MF KIR3DL2+ Cohort 2 KIR3DL2 expressors (n=21) 3 Cohorts (N~100) • Global ORR 28.6% (including 2 CR and 4 PR) At least 2 prior systemic therapies Best overall response Updated ORR 42.9% (including 2 CR
Slide 18: Initiating data-driven strategy in PTCL
Initiating data-driven strategy in PTCL Now Next steps RELAPSED SETTING FRONTLINE Highest unmet medical need Driven by data in the relapsed setting to advance Combination with GemOx into earlier lines (LYSA-sponsored Phase 2 KILT study started in H2 2021) Combination with CHOP SOC: Standard of care,
Slide 19: ANKET & ADC: Advance our innovative R&D pipeline
ANKET® & ADC Advance our innovative R&D pipeline 19
Slide 20: A versatile, fit-for-purpose technology
ANKET® Proprietary NK cell engager platform Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46. Provides proliferation and activation signals targeted to NK cells. Demonstrates better anti-tumor efficacy than approved benchmar
Slide 21: ANKET, a differentiated technology in the NK landscape
ANKET®, a differentiated CHECKPOINT NK CELL technology in the NK landscape INHIBITORS NKp46 ENGAGERS NK cells CD20-IL2v IPH6501 BCMA CD16 HALLMARKS OF NK CELL TUMOR IMMUNITY SAR’514, IPH6401 NK and myeloid cells CD123 CD123 SAR’579, IPH6101 • Natural recognition of cancer cells, as the first line of
Slide 22: Multiple ANKET programs targeting hematological malignancies and solid tumors
ANKET® Multiple ANKET® programs targeting hematological malignancies and solid tumors SAR443579 progresses to Ph2 Growing clinical pipeline • Clinical PoC established in Phase 1/2 in SAR’579 / IPH6101 (CD123) Phase 1/2 R/R AML with complete and durable responses in monotherapy SAR’514 / IPH6401 (BCM
Slide 23: SAR'579 / IPH6101 promising preliminary single agent clinical activity in R/R AML
ANKET® SAR'579 / IPH6101 promising preliminary single agent clinical activity in R/R AML SAR’579 (SAR443579) / IPH6101 is a trifunctional anti-CD123 NKp46xCD16 NK cell engager PHASE 1 / 2 underway in R/R AML, B-cell ALL or HR MDS 82 patients to be enrolled Preliminary efficacy results 43 patients (4
Slide 24: Different Receptors have Different Effects on NK cells
ANKET® Different Receptors have Different Effects on NK cells NKG2D NKp46 CD16 IL-2Rβ DAP10 CD3ζ, FcRγ IL-2Rγ NK cell activation + NK cell activation +++ Proliferation +++ Cytotoxicity Cytotoxicity Cytokines and chemokines Adapted from Lanier, Nature Immunol 2008; Vivier et al., Science, 2004 24
Slide 25: IPH6501, a novel CD20-targeting tetra-specific NK cell engager
ANKET® IPH6501, a novel CD20-targeting tetra-specific natural killer cell engager from ANKET® platform, has started clinical study in B-cell malignancies Phase 1/2 first-in-human, multicenter, in Patients With Relapsed and/or CD20 Refractory Non-Hodgkin Lymphoma Anti- CD20 NCT06088654 First patient
Slide 26: Differentiated ADCs: research pipeline
ADC We are leveraging our antibody expertise by developing differentiated ADCs ADC Research pipeline – Lead asset at pre-IND stage IPH45 (Nectin-4) Pre-IND IPH43 (MICA/B) Phase 1 Research Target (Tumor antigen) Research Target (Coeliac disease) Research
Slide 27: IPH45 is a novel and differentiated Nectin-4 DAR8 exatecan ADC
ADC IPH45 is a novel and differentiated Nectin-4 DAR8 exatecan ADC Progress towards IND in 2024 Binder Payload Exatecan, Proprietary humanized a Topoisomerase I inhibitor anti-Nectin-4 Antibody • Active in EV/MMAE-resistant models • High affinity • Higher Bystander Effect than EV, leading to stronge
Slide 28: IPH45 has potential for improved clinical benefits across multiple tumor types
ADC IPH45 has potential for improved clinical benefits across multiple tumor types Stronger preclinical efficacy than EV with higher bystander effect Packages IND in 2024 H-score 120 H-score 300 • Stronger efficacy than EV Nectin-4 expression in low Nectin-4 PDX Productivity with high models of UC t
Slide 29: Adenosine Pathway: IPH5201 (anti-CD39) and IPH5301 (anti-CD73)
ADENOSINE Adenosine Pathway: IPH5201 (anti-CD39) and IPH5301 (anti-CD73) IPH5301 Perrot et al. 2019 Cell Reports - Allard B. et al. Immunol.l Rev.. 2017 - Vigano S. et al. Front. Immunol. 2019 - Kepp O. et al. EMBO J. 2021 - ATP : adenosine triphosphate - AMP : adenosine monophosphate 29
Slide 30: IPH5201: Phase 2 clinical trial MATISSE initiated
IPH5201 IPH5201: Phase 2 clinical trial MATISSE initiated Phase 1 in advanced solid tumors Preclinical data Phase 2 trial MATISSE ongoing completed (sponsor: AstraZeneca) Best change in tumor size from baseline Non small cell lung cancer (NSCLC) IPH5201 monotherapy IPH5201 + durvalumab Neoadjuvant c
Slide 31: IPH5301: Phase 1 clinical trial ISS CHANCES ongoing
IPH5301 IPH5301: Phase 1 clinical trial ISS CHANCES ongoing Preclinical data Phase 1 CHANCES IST ongoing (sponsor: IPC) IPH5301 epitope translates into superior blocking capacity on both membrane and soluble CD73 and superior T cell activation; IPH5301 has the potential to enhance PD-1 efficacy Adva
Slide 32: Build a sustainable business through partnerships
Build a sustainable business through partnerships 32
Slide 33: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
MONALIZUMAB Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Late-stage clinical trial highlights Monalizumab blocks the NKG2A AstraZeneca initiated Phase 3 trial, PACIFIC-9 inhibitory receptor on both NK cells and with monalizumab + durvalumab in patients with cytoto
Slide 34: Monalizumab development in progress of Phases 2 and 3 trials
MONALIZUMAB Monalizumab development in progress of Phases 2 and 3 trials Covering early stages of lung cancer Stages of the disease NeoCOAST* Data presented: 2022 NeoCOAST-2* 30% major pathological Patients with Stage II to IIIB NSCLC NSCLC response vs. 11% durvalumab. Monalizumab + durvalumab + che
Slide 35: Strategic partnership with AstraZeneca
MONALIZUMAB Strategic partnership with AstraZeneca Monalizumab Amounts received Total amount of the agreement: 1.275 billion US$ Total milestones Milestone Initial payments 250 100 payments Development and regulatory 50 50 400 In US$ million Commercialization 425 Royalties Outside Europe Europe on s
Slide 36: Strategic partnership with AstraZeneca: IPH5201
IPH5201 Strategic partnership with AstraZeneca IPH5201 Milestone payments $60m Potential total amount of the Already received agreement Including $5 million in milestone payment for the launch of the MATISSE Phase 2 trial. $885 million Royalties on sales Outside Europe AstraZeneca will record all sa
Slide 37: Strategic partnership between Sanofi and Innate
ANKET® Strategic partnership between Sanofi and Innate Four molecules licensed to Sanofi plus one undisclosed target remaining under option IPH6101/SAR’579 IPH6401/SAR’514 IPH62 IPH67 OPTION Ongoing CD123 BCMA B7-H3 Target Target programs Phase 1 / 2 in AML Phase 1 / 2 in Multiple Myeloma Research u
Slide 38: Partnership between Takeda and Innate
Partnership between Takeda and Innate Exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) ADC using a panel of selected antibodies developed by Innate Ongoing Undisclosed target programs Preclinical stage – with a primary focus in Celiac disease Paymen
Slide 39: Key takeaways
B innate pharma Key takeaways 39
Slide 40: Key Takeaways
Key Takeaways Create value for patients and shareholders Established expertise in immuno-pharmacology • LACUTAMAB TELLOMAK DATA • Top-line results in mycosis fungoides to be shared at ASCO • Regulatory strategy • EXPAND ANKET® CLINICAL PORTFOLIO – LEAD IN HEMATOLOGY INDICATIONS • First patient dosed
Slide 41: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) Delivering across our strategic objectives • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201 (CD39) MATISSE | Phase 2 readout (AZ) • IPH5301 (CD73) | Phase 1 data • SAR’579 / IPH6101 ANKET® (CD123) | Next steps (S
Slide 42: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA